ProCE Banner Activity

Key Insights on CD38 and BCMA as Targets for Therapy in Multiple Myeloma

Clinical Thought

Expert faculty answer questions from a live event on use of quadruplet therapies in the management of transplant-eligible and transplant-ineligible newly diagnosed multiple myeloma, management of infectious risk with immunotherapies, and the future of belantamab mafodotin.

Released: August 28, 2024

Expiration: August 27, 2025

Share

Faculty

Craig Emmitt Cole

Craig Emmitt Cole, MD

Associate Professor of Medicine
Department of Oncology
Karmanos Cancer Institute
Wayne State University School of Medicine
Detroit, Michigan

Thomas G. Martin

Thomas G. Martin, MD

Clinical Professor of Medicine
Associate Chief, Division of Hematology/Oncology
Co-Lead, Cancer Immunology and Immunotherapy Program
Helen Diller Family Comprehensive Cancer Center
University of California, San Francisco
San Francisco, California

Noopur Raje

Noopur Raje, MD

Professor of Medicine
Harvard Medical School
Director, Center for Multiple Myeloma
Massachusetts General Hospital
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by an educational grant from Sanofi.

Sanofi

Disclosure

Primary Author

Craig Emmitt Cole, MD

Associate Professor of Medicine
Department of Oncology
Karmanos Cancer Institute
Wayne State University School of Medicine
Detroit, Michigan

Craig Emmitt Cole, MD: consultant/advisor/speaker: AbbVie, Binding Site, Genentech, GlaxoSmithKline, Janssen, Pfizer, Sanofi; researcher: GlaxoSmithKline.

Noopur Raje, MD

Professor of Medicine
Harvard Medical School
Director, Center for Multiple Myeloma
Massachusetts General Hospital
Boston, Massachusetts

Noopur Raje, MD: consultant/advisor/speaker: AstraZeneca, Bristol Myers Squibb, Genentech, Johnson & Johnson, Pfizer, Sanofi.